140 related articles for article (PubMed ID: 28164557)
1. The Detection of Urinary Podocytes from Drug-Induced Glomerular Thrombotic Microangiopathy in Advanced Cancer Patients.
Usui J; Yokoyama C; Hagiwara M; Hirayasu K; Kojima T; Yoshino T; Nishiyama H; Hara M; Yamagata K
Clin Lab; 2016 Dec; 62(12):2413-2417. PubMed ID: 28164557
[TBL] [Abstract][Full Text] [Related]
2. Gemcitabine-induced thrombotic microangiopathy with nephrotic syndrome.
Katagiri D; Hinoshita F
CEN Case Rep; 2018 Nov; 7(2):217-220. PubMed ID: 29766468
[TBL] [Abstract][Full Text] [Related]
3. Reversible renal-limited thrombotic microangiopathy due to gemcitabine-dexamethasone-cisplatin therapy: a case report.
Nishikubo M; Shimomura Y; Hiramoto N; Sawamura N; Yamaguchi T; Hara S; Ishikawa T
BMC Nephrol; 2021 May; 22(1):175. PubMed ID: 33980166
[TBL] [Abstract][Full Text] [Related]
4. Clinicopathological spectrum of kidney diseases in cancer patients treated with vascular endothelial growth factor inhibitors: a report of 5 cases and review of literature.
Usui J; Glezerman IG; Salvatore SP; Chandran CB; Flombaum CD; Seshan SV
Hum Pathol; 2014 Sep; 45(9):1918-27. PubMed ID: 25087655
[TBL] [Abstract][Full Text] [Related]
5. Bevacizumab-associated glomerular microangiopathy.
Person F; Rinschen MM; Brix SR; Wulf S; Noriega MLM; Fehrle W; Schmitz J; Schwarz A; Ivanyi P; Steinmetz OM; Reinhard L; Hoxha E; Zipfel PF; Bräsen JH; Wiech T
Mod Pathol; 2019 May; 32(5):684-700. PubMed ID: 30552416
[TBL] [Abstract][Full Text] [Related]
6. Renal thrombotic microangiopathy and podocytopathy associated with the use of carfilzomib in a patient with multiple myeloma.
Hobeika L; Self SE; Velez JC
BMC Nephrol; 2014 Sep; 15():156. PubMed ID: 25267524
[TBL] [Abstract][Full Text] [Related]
7. Thrombotic microangiopathy, cancer, and cancer drugs.
Izzedine H; Perazella MA
Am J Kidney Dis; 2015 Nov; 66(5):857-68. PubMed ID: 25943718
[TBL] [Abstract][Full Text] [Related]
8. Proteinuria in thrombotic microangiopathy is associated with partial podocytopathy.
Moore M; Afolayan-Oloye O; Kroneman O; Li W; Kanaan HD; Zhang PL
Ultrastruct Pathol; 2023 May; 47(3):219-226. PubMed ID: 36906888
[TBL] [Abstract][Full Text] [Related]
9. VEGF-VEGFR2 inhibitor-associated hyaline occlusive glomerular microangiopathy: a Japanese single-center experience.
Ozawa M; Ohtani H; Komatsuda A; Wakui H; Takahashi N
Clin Exp Nephrol; 2021 Nov; 25(11):1193-1202. PubMed ID: 34115234
[TBL] [Abstract][Full Text] [Related]
10. Renal-limited thrombotic microangiopathy after switching from bevacizumab to ramucirumab: a case report.
Yamada R; Okawa T; Matsuo K; Suzuki M; Mori N; Mori K
BMC Nephrol; 2019 Jan; 20(1):14. PubMed ID: 30634936
[TBL] [Abstract][Full Text] [Related]
11. Thrombotic microangiopathy associated with gemcitabine use: Presentation and outcome in a national French retrospective cohort.
Daviet F; Rouby F; Poullin P; Moussi-Francès J; Sallée M; Burtey S; Mancini J; Duffaud F; Sabatier R; Pourroy B; Grandvuillemin A; Grange S; Frémeaux-Bacchi V; Coppo P; Micallef J; Jourde-Chiche N
Br J Clin Pharmacol; 2019 Feb; 85(2):403-412. PubMed ID: 30394581
[TBL] [Abstract][Full Text] [Related]
12. A case of progressive hypertension preceding gemcitabine-associated thrombotic microangiopathy complicated by acute kidney injury and stroke.
Phelan PJ; Liew A; Magee C
Ren Fail; 2009; 31(8):743-4. PubMed ID: 19814643
[TBL] [Abstract][Full Text] [Related]
13. Urinary and glomerular podocytes in patients with chronic kidney diseases.
Hanamura K; Tojo A; Fujita T
Clin Exp Nephrol; 2014 Feb; 18(1):95-103. PubMed ID: 23670304
[TBL] [Abstract][Full Text] [Related]
14. Gemcitabine-related thrombotic microangiopathy: a single-centre retrospective series.
Leal F; Macedo LT; Carvalheira JB
J Chemother; 2014 Jun; 26(3):169-72. PubMed ID: 24091354
[TBL] [Abstract][Full Text] [Related]
15. Two cases of idiopathic steroid-resistant nephrotic syndrome complicated with thrombotic microangiopathy.
Nishi K; Sato M; Ogura M; Okutsu M; Ishikura K; Kamei K
BMC Nephrol; 2020 Aug; 21(1):323. PubMed ID: 32746791
[TBL] [Abstract][Full Text] [Related]
16. Gemcitabine-induced thrombotic microangiopathy.
Richmond J; Gilbar P; Abro E
Intern Med J; 2013 Nov; 43(11):1240-2. PubMed ID: 24237646
[TBL] [Abstract][Full Text] [Related]
17. Bevacizumab-induced thrombotic microangiopathy and nephrotic syndrome.
Shimamura Y; Maeda T; Takizawa H
Clin Exp Nephrol; 2019 Jan; 23(1):142-143. PubMed ID: 29882112
[No Abstract] [Full Text] [Related]
18. Podocyturia parallels proximal tubule dysfunction in type 2 diabetes mellitus patients independently of albuminuria and renal function decline: A cross-sectional study.
Petrica L; Vlad M; Vlad A; Gluhovschi G; Gadalean F; Dumitrascu V; Popescu R; Gluhovschi C; Matusz P; Velciov S; Bob F; Ursoniu S; Vlad D
J Diabetes Complications; 2017 Sep; 31(9):1444-1450. PubMed ID: 28161386
[TBL] [Abstract][Full Text] [Related]
19. Antineoplastic agents and thrombotic microangiopathy.
Garcia G; Atallah JP
J Oncol Pharm Pract; 2017 Mar; 23(2):135-142. PubMed ID: 26854265
[TBL] [Abstract][Full Text] [Related]
20. Characteristic morphological changes in anti-VEGF therapy-induced glomerular microangiopathy.
Pfister F; Amann K; Daniel C; Klewer M; Büttner A; Büttner-Herold M
Histopathology; 2018 Dec; 73(6):990-1001. PubMed ID: 30014486
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
